Advertisement

Archives of Dermatological Research

, Volume 311, Issue 8, pp 589–594 | Cite as

Macrophage migration inhibitory factor polymorphism (rs755622) in alopecia areata: a possible role in disease prevention

  • Fateme Rajabi
  • Mahsa M. Amoli
  • Reza M. RobatiEmail author
  • Mina Almasi-nasrabadi
  • Navid Jabalameli
Original Paper

Abstract

Alopecia areata (AA) is an organ-specific autoimmune disease that targets the bulb of the hair follicles and results in non-scarring hair loss that can range from patchy lesions to involvement of the entire scalp. AA develops when the hair follicles lose their physiologic state of immune privilege. One of the key factors that help in maintaining this immune privilege by suppressing natural killer cells is macrophage migration inhibitory factor (MIF). Surprisingly, MIF is also known to provoke autoimmunity by upregulating cytokines. To address this dilemma and understand the exact nature of the involvement of MIF in disease pathogenesis we investigated the association of MIF gene polymorphisms (− 173 G > C, rs755622) with AA by conducting a case–control study of 274 subjects. We observed that the frequency of the C allele in the patients was significantly lower than the control group (0.15, 0.23, respectively, p = 0.01) and the combined frequencies of the CC and GC genotypes (dominant Mendelian pattern) had the most prevalent difference between the two groups (odds ratio 0.60, 95% confidence interval 0.36–0.99; p = 0.048).Since the C allele is associated with higher MIF transcription levels, this could infer that MIF is more likely to attribute to the preservation of the immune privilege rather than acting as a proinflammatory factor.

Keywords

Immune privilege Autoimmunity Natural killer cells Genetic association study Hair follicle 

Notes

Acknowledgements

We wish to present our special thanks to Dr Azin Ayatollahi for her contributions that greatly assisted the research.

Author contributions

FR, MMA, MA, and NJ performed the research. RMR, MMA designed the research study. FR, MA, and NJ analyzed the data. FR, MMA and RMR wrote the paper. All authors have read and approved the final manuscript.

Funding

This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval (research involving human participants and/or animals)

The study was approved by the Ethics commitee of Shahid Beheshti University of Medical Sciences.

Informed consent

A written informed consent was obtained from all participants according to the declaration of Helsinki.

References

  1. 1.
    Apte RS, Sinha D, Mayhew E, Wistow G, Niederkorn J (1998) Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160:5693–5696Google Scholar
  2. 2.
    Arcuri F, Cintorino M, Carducci A, Papa S, Riparbelli M, Mangioni S, Di Blasio A, Tosi P, Vigano P (2006) Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction 131:175–182CrossRefGoogle Scholar
  3. 3.
    Denkinger CM, Metz C, Fingerle-Rowson G, Denkinger MD, Forsthuber T (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp (Warsz) 52:389–400Google Scholar
  4. 4.
    Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheumatol 46:2402–2409CrossRefGoogle Scholar
  5. 5.
    Donn R, Shelley E, Ollier W, Thomson W, Group BPRS (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785CrossRefGoogle Scholar
  6. 6.
    Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE (2004) Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 123:484–487CrossRefGoogle Scholar
  7. 7.
    Donnelly SC, Bucala R (1997) Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 3:502–507CrossRefGoogle Scholar
  8. 8.
    Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF (2004) Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 31:268–273Google Scholar
  9. 9.
    Gilhar A (2010) Collapse of immune privilege in alopecia areata: coincidental or substantial? J Invest Dermatol 130:2535–2537CrossRefGoogle Scholar
  10. 10.
    Greven D, Leng L, Bucala R (2010) Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Tar 14:253–264CrossRefGoogle Scholar
  11. 11.
    Illescas O, Gomez-Verjan JC, García-Velázquez L, Govezensky T, Rodriguez-Sosa M (2018) Macrophage migration inhibitory factor – 173 G/C polymorphism: a global meta-analysis across the disease spectrum. Front Genet 9:55CrossRefGoogle Scholar
  12. 12.
    Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R (2004) Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 164:623–634CrossRefGoogle Scholar
  13. 13.
    Ito T, Ito N, Saathoff M, Stampachiacchiere B, Bettermann A, Bulfone-Paus S, Takigawa M, Nickoloff BJ, Paus R (2005) Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol 125:1139–1148CrossRefGoogle Scholar
  14. 14.
    Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R (2008) Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 128:1196–1206CrossRefGoogle Scholar
  15. 15.
    Kang H, Wu W-Y, Lo BK, Yu M, Leung G, Shapiro J, McElwee KJ (2010) Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol 130:2677–2680CrossRefGoogle Scholar
  16. 16.
    Leech M, Metz C, Bucala R, MorAnd EF (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheumatol 43:827–833CrossRefGoogle Scholar
  17. 17.
    Matia-García I, Salgado-Goytia L, Muñoz-Valle JF, García-Arellano S, Hernández-Bello J, Salgado-Bernabé AB, Parra-Rojas I (2015) Macrophage migration inhibitory factor promoter polymorphisms (-794 CATT 5–8 and-173 G> C): relationship with mRNA expression and soluble MIF levels in young obese subjects. Dis Markers 2015:461208CrossRefGoogle Scholar
  18. 18.
    Meyer K, Klatte J, Dinh H, Harries M, Reithmayer K, Meyer W, Sinclair R, Paus R (2008) Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 159:1077–1085Google Scholar
  19. 19.
    Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR (2014) Lifetime incidence risk of alopecia areata estimated at 2.1 percent by rochester epidemiology project, 1990–2009. J Invest Dermatol 134:1141CrossRefGoogle Scholar
  20. 20.
    Morales-Zambrano R, Bautista-Herrera LA, De la Cruz-Mosso U, Villanueva-Quintero GD, Padilla-Gutiérrez JR, Valle Y, Parra-Rojas I, Rangel-Villalobos H, Gutiérrez-Ureña SR, Muñoz-Valle JF (2014) Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5–8 and – 173 G > C): association with MIF and TNFα in psoriatic arthritis. Int J Clin Exp Med 7:2605Google Scholar
  21. 21.
    Murakami H, Akbar SMF, Matsui H, Onji M (2001) Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 31:337–343CrossRefGoogle Scholar
  22. 22.
    Namazi MR, Fallahzadeh MK, Shaghelani H, Kamali-Sarvestani E (2010) Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris. Int J Dermatol 49:146–148CrossRefGoogle Scholar
  23. 23.
    Ohwatari R, Inuyama Y, Fukuda S, Onoé K, Iwabuchi K, Nishihira J (2001) Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener’s granulomatosis and relapsing polychondritis. Ann Oto Rhinol Laryn 110:1035–1040CrossRefGoogle Scholar
  24. 24.
    Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE, McMichael AJ, Randall VA (2004) Alopecia areata investigational assessment guidelines-part II. J Am Acad Dermatol 51:440–447CrossRefGoogle Scholar
  25. 25.
    Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H, Singh P, Lee A, Chen WV (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466:113CrossRefGoogle Scholar
  26. 26.
    Rajabi F, Drake L, Senna M, Rezaei N (2018) Alopecia areata: a review of disease pathogenesis. Br J Dermatol 179:1033–1048CrossRefGoogle Scholar
  27. 27.
    Rajabi F, Amoli MM, Robati RM, Almasi-Nasrabadi M, Jabalameli N, Moravvej H (2019) The Association between Genetic Variation in Wnt Transcription Factor TCF7L2 (TCF4) and Alopecia Areata. Immunol Invest.  https://doi.org/10.1080/08820139.2019.1597109 Google Scholar
  28. 28.
    Repp AC, Mayhew ES, Apte S, Niederkorn JY (2000) Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 165:710–715CrossRefGoogle Scholar
  29. 29.
    Saeedi M, Amoli M, Robati R, Sayahpour F, Namazi N, Toossi P (2013) Macrophage migration inhibitory factor gene polymorphism is not associated with pemphigus vulgaris in Iranian patients. J Eur Acad Dermatol Venereol 27:1127–1131CrossRefGoogle Scholar
  30. 30.
    Salem SA, Asaad MK, Elsayed SB, Sehsah HM (2016) Evaluation of macrophage migration inhibitory factor (MIF) levels in serum and lesional skin of patients with alopecia areata. Int J Dermatol 55:1357–1361CrossRefGoogle Scholar
  31. 31.
    Shimizu T, Abe R, Ohkawara A, Nishihira J (1999) Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immun 104:659–664CrossRefGoogle Scholar
  32. 32.
    Shimizu T, Hizawa N, Honda A, Zhao Y, Abe R, Watanabe H, Nishihira J, Nishimura M, Shimizu H (2005) Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun 6:285–289CrossRefGoogle Scholar
  33. 33.
    Shimizu T, Mizue Y, Abe R, Watanabe H, Shimizu H (2002) Increased macrophage migration inhibitory factor (MIF) in the sera of patients with extensive alopecia areata. J Invest Dermatol 118:555CrossRefGoogle Scholar
  34. 34.
    Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A, Shimizu H (2001) High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116:989–990CrossRefGoogle Scholar
  35. 35.
    Shimizu T, Nishihira J, Mizue Y, Nakamura H, Abe R, Watanabe H, Ohkawara A, Shimizu H (2001) High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116:989–990CrossRefGoogle Scholar
  36. 36.
    Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, Miljkovic D, Metz C, Mangano K, Papaccio G (2008) Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 215:665–675CrossRefGoogle Scholar
  37. 37.
    Streilein JW (2003) Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3:879CrossRefGoogle Scholar
  38. 38.
    Younan DNA, Agamia N, Elshafei A, Ebeid N (2015) Serum level of macrophage migration inhibitory factor (MIF) in Egyptians with alopecia areata and its relation to the clinical severity of the disease. J Clin Lab Anal 29:74–79CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Fateme Rajabi
    • 1
    • 3
  • Mahsa M. Amoli
    • 2
  • Reza M. Robati
    • 1
    Email author
  • Mina Almasi-nasrabadi
    • 1
  • Navid Jabalameli
    • 3
  1. 1.Skin Research CenterShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences InstituteTehran University of Medical SciencesTehranIran
  3. 3.Network of Dermatology Research (NDR)Universal Scientific Education and Research Network (USERN)TehranIran

Personalised recommendations